Skip to main content
. 2021 Sep 8;43(5):717–728. doi: 10.1007/s00281-021-00888-3

Fig. 3.

Fig. 3

Treatment of primary IgAN (adapted from KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF GLOMERULAR DISEASES. Kidney Int Suppl 2021 in press.). *Specific considerations apply to some ethnic groups: (1) if Japanese, consider tonsillectomy; (2) if Chinese consider mycophenolate mofetil as a corticosteroid-sparing agent